A major breakthrough in cancer therapy has been achieved by directing ICBs to the PD-L1/PD-1 axis, well recognized for its pivotal roles in shutting down potential T cell activities against cancer cells [1,2,3]. The gene discussed is CD274; the disease is cancer.